Torex Resources Celebrates Listing on the New York Stock Exchange
Torex Resources (NYSE: TXR) has officially listed on the New York Stock Exchange, with CEO Andrew Snowden participating in the opening bell ceremony.
Stocks · News reference
Financial institutions including Deutsche Bank, Stifel, and UBS issued updated price targets and ratings for 10x Genomics on November 6, 2026, following the company's third-quarter earnings release.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Torex Resources (NYSE: TXR) has officially listed on the New York Stock Exchange, with CEO Andrew Snowden participating in the opening bell ceremony.
10x Genomics has entered into two new research collaborations with Charité – Universitätsmedizin Berlin, the German Rheumatology Research Center Berlin (DRFZ), and Seoul National University to identify blood-based biomarkers for autoimmune diseases.
Analyst firm Stephens has initiated coverage on 10x Genomics (TXG) with a 'Hold' rating and a price target of $65.
10x Genomics, Inc. announced that Fudan University Shanghai Cancer Center and Shanghai Precision Diagnostics Co. Ltd will utilize its Xenium platform in a 24-month study to identify biomarkers for breast cancer neoadjuvant therapy response.
Torex Resources Inc. has received approval to list its common shares on the New York Stock Exchange (NYSE), with trading expected to commence on November 17, 2026.